

WEIGHTED POSTERIOR ODDS: A DATA SUMMARY FOR DECISION MAKING

GENE PENNELLO, PhD

Division of Imaging Diagnostics & Software Reliability U.S. Food and Drug Administration Center for Devices and Radiological Health Office of Science and Engineering Laboratories

Bayesian Biostatistics 2024, Rockville, MD – USA Thursday, 10/24/2024, 11:55 AM - 12:15 PM

Disclosure / Disclaimer

- The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services.
- This is a contribution of the U.S. Food and Drug Administration is not subject to copyright.


FD/

Outline

FDA

- Bayesian model, loss function for testing a 1-sided hypothesis
 - Bayes rule critical region: weighted posterior odds is the focal point
 - Normal data, linear loss as a special case
 - Numerical examples
- Bayes model, loss function for testing a 1-sided comparison of means
 - Bayes rule critical region: weighted posterior odds is the focal point
 - Normal data, linear loss as a special case
 - Numerical examples
- Linear loss in testing ⇔ squared-error loss in estimation connection
- Discussion

Bayesian Model



FDA

Hypothesis Test $H: \mu \leq \mu_0$ $A: \mu > \mu_0$

Loss Model

FDA

Loss Function
$$L(a, \mu) = L_a(\mu)$$
Decision $a = I\left(\underline{y} \in R\right)$ Critical Region $R = \left\{\underline{y}: \operatorname{accept} A: \mu > \mu_0 \text{ as true}\right\}$

Type 1 Loss
$$L_1(\mu) = \mathbf{k}l(\mu_0, \mu)I(\mu \le \mu_0)$$
Type 2 Loss $L_0(\mu) = l(\mu, \mu_0)I(\mu > \mu_0)$ Distance Function $l(u, v)$ $\begin{cases} = 0, u \le v \\ > 0, u > v \end{cases}$

k = type 1 to type 2 error loss (or seriousness) ratio

Г

Bayes Rule Critical Region

$$\widetilde{R} = \left\{ \underline{\mathbf{y}} : W\left(\underline{\mathbf{y}}, \mu_0\right) > k \right\}$$

where

$$W\left(\underline{y},\mu_{0}\right) = \frac{\int_{\mu_{0}}^{\infty} l(\mu,\mu_{0})\pi\left(\mu|\underline{y}\right)d\mu}{\int_{-\infty}^{\mu_{0}} l(\mu_{0},\mu)\pi\left(\mu|\underline{y}\right)d\mu} = \text{weighted posterior odds of } A$$

$$\pi\left(\mu|\underline{y}\right) = \text{posterior of } \mu|\underline{y}$$

FDA

Bayes Rule Critical Region

$$\tilde{R} = \left\{ \underline{\boldsymbol{y}} : W\left(\underline{\boldsymbol{y}}, \mu_0\right) > k \right\}$$


FDA

Note
$$W(\underline{y}, \mu_0) = \sup_k \{k: W(\underline{y}, \mu_0) > k\}$$

= supremum of the values of k for which
Bayes rule accepts $A: \mu > \mu_0$.

Interpretation

- If $W(\underline{y}, \mu_0) = \mathbf{100}$, then the data support accepting A when
 - type 1 error is no more than 100 times more serious than type 2 error, where
 - type 1 error = falsely accepting $A: \mu > \mu_0$
 - type 2 error = falsely not accepting $A: \mu > \mu_0$
- $W(\underline{y}, \mu_0)$ measures the evidence against H and in favor of A on the scale of
 - the trade-off between the two potential decision errors of
 - falsely accepting A (type 1) and falsely not accepting A (type 2).
- In contrast, the *p* value measures evidence against *H*, but not on the scale of the trade-off between the potential decision errors.
- Thus, for decision making, the p value is arguably less interpretable than $W(\mathbf{y}, \mu_0)$.



Bayes Rule Critical Region under Linear Loss

$$\widetilde{R} = \left\{ \underline{\mathbf{y}} : W\left(\underline{\mathbf{y}}, \mu_0\right) > k \right\}$$


where

$$W\left(\underline{y},\mu_{0}\right) = \frac{\int_{\mu_{0}}^{\infty} (\mu - \mu_{0})\pi\left(\mu|\underline{y}\right)d\mu}{\int_{-\infty}^{\mu_{0}} (\mu_{0} - \mu)\pi\left(\mu|\underline{y}\right)d\mu} = \text{weighted posterior odds of } A$$

$$\pi\left(\mu|\underline{y}\right) = \text{posterior of } \mu|\underline{y}$$

FDA

Normal Data; Diffuse Prior



FDA

Prior (Box-Tiao) $\pi(\mu, \tau) \propto \tau^{-1}$

Normal Data; Box-Tiao Prior

Posterior

FDA

$$\pi\left(\mu,\tau|\underline{y}\right) = \pi\left(\mu|\tau,\underline{y}\right)\pi\left(\tau|\underline{y}\right)$$
$$\mu|\tau,\underline{y}\sim N(\overline{y},\tau_{\overline{y}}^{-1})$$

 $\tau |\underline{\mathbf{y}} \sim \Gamma\left(\frac{f}{2}, \frac{fs^2}{2}\right)$

Bayes Rule Critical Region

FDA

$$\begin{split} \widetilde{R} &= \left\{ \underline{y} \colon W\left(\underline{y}, \mu_0\right) > k \right\} \\ W\left(\underline{y}, \mu_0\right) &= M(t, f) / M(-t, f) \\ t &= \sqrt{n}(\overline{y} - \mu_0) / s \\ f &= n - 1 \\ M(t, f) &= (f - 1)(t^2 + f)g(z, f) + tG(z, f) \\ g(\bullet, \nu) &= \text{density of Student-}t \text{ with } \nu \text{ dof} \\ G(\bullet, \nu) &= \text{cumulative dist'n of Student-}t \text{ with } \nu \text{ dof} \end{split}$$



FDA

$$\begin{split} \widetilde{R} &= \left\{ \underline{y} : W\left(\underline{y}, \mu_0\right) > k \right\} \\ W\left(\underline{y}, \mu_0\right) &= M(z)/M(-z) \\ z &= \sqrt{n}(\overline{y} - \mu_0)/\sigma \\ M(z) &= \varphi(z) + z\Phi(z) = \lim_{f \to \infty} M(t, f) \\ \varphi(\bullet) &= \text{density of } N(0, 1) \text{ variable} \\ \Phi(\bullet) &= \text{cumulative dist'n of } N(0, 1) \text{ variable} \end{split}$$

Interval Estimation

• $\mathbf{kCI} = (\widetilde{\mu}_L, \widetilde{\mu}_U) = \text{values of } \mu_0 \text{ for which neither } A: \mu > \mu_0 \text{ nor } A': \mu < \mu_0$ can be accepted based on the hypothesis tests of $H: \mu \leq \mu_0$ and $H': \mu \geq \mu_0$.

FD/

• When k > 1 is the same for both hypothesis tests,

$$\tilde{\mu}_L$$
 satisfies $W\left(\underline{y}, \tilde{\mu}_L\right) = k$
 $\tilde{\mu}_U$ satisfies $W\left(\underline{y}, \tilde{\mu}_U\right) = k^{-1}$

• For normal data, linear losses, and diffuse Box-Tiao prior,

$$kCI = \overline{y} \pm t_k s / \sqrt{n}$$
, where t_k satisfies $\frac{M(t_k, f)}{M(-t_k, f)} = k$

Numerical Examples

FDA

$$\overline{y} = n^{-1} \Sigma y_i$$
, $s^2 = f^{-1} \Sigma (y_i - \overline{y})^2$, $f = n - 1$ or ∞ , $t = \sqrt{n} (\overline{y} - \mu_0)/s$,

$$kCI = \overline{y} \pm t_k s / \sqrt{n}$$
, where t_k satisfies $\frac{M(t_k, f)}{M(-t_k, f)} = k$

Two-Sample Comparison of Means

FDA

Data

$$y_{gi} \sim N(\mu_{g}, \tau^{-1}), \tau = \sigma^{-2}$$
Hypothesis Test

$$\delta = \mu_{2} - \mu_{1}$$
Prior (Box-Tiao)

$$\mu_{g} \sim N(\mu_{0}, \tau_{\mu}^{-1})$$

$$H: \delta \leq \delta_{0}$$

$$A: \delta > \delta_{0}$$

$$A: \delta > \delta_{0}$$

Bayes Rule Critical Region, Linear Loss

$$\begin{split} \tilde{R} &= \left\{ \underline{y} : W\left(\underline{y} ; \delta_0\right) > k \right\} \\ W\left(\underline{y} ; \delta_0\right) &= W(t, f; \delta_0) \\ t &= \left(\overline{d} - \delta_0\right) / s_{\overline{d}} \\ s_{\overline{d}}^2 &= 2s^2 / n \\ s^2 &= f^{-1} \Sigma \Sigma \left(y_{ai} - \overline{y}_a\right)^2 \\ f &= n - 1 \end{split}$$

FDA



$$W(t, f; \delta_0) = \sup_k \{k: W(t, f; \delta_0) > k \}$$

= supremum of the values of k at which

 $A: \delta > \delta_0$ is accepted by Bayes rule.

FD/

- If $W(t, f; \delta_0) = 100$, then the data support accepting A when
 - type 1 error is no more than <u>100 times more serious</u> than type 2 error, where
 - type 1 error = falsely accepting $A: \delta > \delta_0$
 - type 2 error = falsely not accepting $A: \delta > \delta_0$

Numerical Examples

FDA

$$t_{\gamma}(f) = \gamma$$
th quantile of Student-*t* with *f* dof
 $t_{0.975}(\infty) = 1.96$: $W(1.96, \infty; \delta_0) \cong 100$
 $t_{0.95}(\infty) = 1.645 W(1.645, \infty; \delta_0) \cong 50$
 $t_{0.995}(\infty) = 2.576 W(2.576, \infty; \delta_0) \cong 500$

Interval Estimation

• $\mathbf{k}\mathbf{C}\mathbf{I} = (\tilde{\delta}_L, \tilde{\delta}_U) = \text{values of } \mu_0 \text{ for which neither } A: \delta > \delta_0 \text{ nor } A': \delta < \delta_0$ can be accepted based on the hypothesis tests of $H: \delta \leq \delta_0$ and $H': \delta \geq \delta_0$.

FD/

• When k > 1 is the same for both hypothesis tests,

 $\tilde{\delta}_L$ satisfies $W(t, f; \tilde{\delta}_L) = k$ $\tilde{\delta}_U$ satisfies $W(t, f; \tilde{\delta}_U) = k^{-1}$

• For normal data, linear losses, and diffuse Box-Tiao prior,

 $kCI = \overline{d} \pm t_k s_k \sqrt{2/n}$, where t_k satisfies $W(t_k, f; \delta_0) = k$

Squared-Error Loss for Estimation

FDA

- **Result**. Squared-error loss for estimation and linear loss for testing yield the same interval estimate $(\tilde{\delta}_L, \tilde{\delta}_U)$:
 - $\tilde{\delta}_L \text{ satisfies } W\left(\underline{y}; \tilde{\delta}_L\right) = k$
 - $\tilde{\delta}_U$ satisfies $W\left(\underline{y}; \tilde{\delta}_U\right) = k^{-1}$

Squared Error Loss
$$L(e, \delta) = \begin{cases} k(e - \delta)^2, e \ge \delta \\ (\delta - e)^2, e < \delta \end{cases}$$

Posterior Expected Loss $E[L(e,\delta)] = \int_{-\infty}^{e} k(e-\delta)^2 \pi \left(\delta|\underline{y}\right) d\delta + \int_{e}^{\infty} (\delta-e)^2 \pi \left(\delta|\underline{y}\right) d\delta$

$$\frac{\partial}{\partial e} E[L(e,\delta)] \stackrel{\text{Leibnitz}}{=} 2k \int_{-\infty}^{e} (e-\delta)\pi \left(\delta | \underline{y} \right) d\delta - 2 \int_{e}^{\infty} (\delta-e)\pi \left(\delta | \underline{y} \right) d\delta \stackrel{\text{set}}{=} 0$$

$$\therefore \quad k = \int_{e}^{\infty} (\delta-e)\pi \left(\delta | \underline{y} \right) d\delta / \int_{-\infty}^{e} (e-\delta)\pi \left(\delta | \underline{y} \right) d\delta \equiv W \left(\underline{y}; \delta_{0} \right)$$

Dixon DO, Duncan DB. Minimum Bayes Risk *t* -Intervals for Multiple Comparisons, *JASA* 1975; 70 (352), 822-831. Dixon DO. Interval Estimates Derived from Bayes Testing Rules. *JASA* 1976; 71 (354), 406-408.

Discussion

FDA

- Summaries of evidence for a hypothesis include
 - the *p* value, the smallest allowed type 1 error level for accepting a hypothesis,
 - weighted posterior odds (WPO), the largest allowed type-1-to-type-2-error-seriousness ratio (k) for accepting a hypothesis.
- Arguably, WPO is of more interest to decision makers than the p value.
 - Decision makers make value judgments about the consequent benefits and harms of actions that would be taken if a hypothesis were accepted as true or not.
 - Likewise, WPO summarizes evidence for a hypothesis in terms of relative consequences of decision errors, where "consequence" = "seriousness", "importance", "harm", "risk", "loss"...
- For stakeholders (e.g., regulator, payer, provider, policy maker, manufacturer, doctor, patient), the observed WPO in a study
 - may be compared with their own value judgment of k.
 - should facilitate better discussion as to whether to accept a hypothesis as true or not.

Discussion (continued)

FDA

• **Proposal:** Set preliminary value of k by FDA regulatory pathway, e.g.,

Product	k ₁	k ₂	k ₃	k_4
Drug / Biologic	Full approval	Accelerated approval	Orphan	
		Biosimilar		
Medical Device	Class III	Class II	Humanitarian	Class I
	Breakthrough	Lab developed test	EUA	Wellness
			Wearable	

$$k_1 > k_2 > k_3 > k_4 \gg 1$$

Discussion (*continued***)**



- The k-ratio method was developed by David B. Duncan and his students for Bayes rule multiple comparisons of means (MCM) problems assuming
 - (1) additive linear losses of the component comparisons,
 - (2) prior exchangeability of the means
- MCM Problems
 - Comparisons of Means in a 1-Way Array (Waller)
 - $W(t_{ij}, F, q, f; \delta_0) = WPO \text{ for } \delta_{ij} > \delta_0$
 - Comparisons of Treatments with a Control (Brant)
 - W($t_{i0}, F_T, F_G, q_T, q_G, f; \delta_0$) = WPO for $\delta_{i0} > \delta_0$ ($q_G = 1$)
 - Largest Mean Problem (Ranking and Selection) (Bland)
 - Comparisons of Means in a 2-Way Array (Pennello)
 - W($t_{ij,k}, t_{ij}$, $F_A, F_B, F_C, q_A, q_B, q_C, f; \delta_0$) = WPO for $\delta_{ij,k} > \delta_0$

Discussion (continued)

FD/

Extra Results. If distance function l(u, v) is constant when u > v and 0 otherwise, then

(1)
$$W\left(\underline{y}, \mu_0\right) = \pi_A (\mathbf{1} - \pi_A)^{-1}$$
 is the posterior odds of $A: \mu > \mu_0$, where $\pi_A = \Pr\left(\mu > \mu_0 | \underline{y}\right)$,

(2) specifying k is the same as specifying the posterior probability of $\pi_A = k/(1+k)$ at which A is accepted.

(3) in the one sample case with τ known and $\pi(\mu) \propto 1$, $W(\underline{y}, \mu_0) = Bayes$ factor because then $\pi(\mu|\underline{y}) = f(\underline{y}|\mu)$ numerically.



Questions?

Gene.Pennello@fda.hhs.gov

